What does big pharma Johnson & Johnson (NYSE: JNJ) have in common with biotech Moderna (NASDAQ: MRNA)? Last week, however, Johnson & Johnson said it would discontinue its adult RSV program. Could the J&J news eventually translate into billions of dollars for Moderna?